- Home
- ADXN vs SNSE Comparison
ADXN vs SNSE Comparison
Compare ADXN & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | SNSE |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 12.2M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ADXN | SNSE |
|---|---|---|
| Price | $7.25 | $35.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 2.8K | ★ 539.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $0.25 |
| 52 Week High | $12.05 | $34.99 |
Technical Indicators
Market Signals| Indicator | ADXN | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 89.77 |
| Support Level | $6.82 | $7.94 |
| Resistance Level | $8.54 | N/A |
| Average True Range (ATR) | 0.28 | 2.48 |
| MACD | -0.06 | 2.82 |
| Stochastic Oscillator | 34.21 | 92.19 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).